Calidi Biotherapeutics (CLDI) CEO Eric Poma Receives Option Award

What Happened

• Eric E. Poma, Chief Executive Officer of Calidi Biotherapeutics (CLDI), was granted 32,000 incentive stock options on August 17, 2026. The options have an exercise price of $1.36 per share, which equals the company's closing common stock price on the grant date. This is a grant/award (derivative) — not a purchase or sale — and was reported on Form 4 filed August 19, 2026.

Key Details

• Transaction date: 2026-08-17; Form 4 filed: 2026-08-19 (timely filing).
• Grant: 32,000 incentive stock options; exercise price: $1.36 (equal to closing price on grant date) — no intrinsic value at grant.
• Vesting: 25% vests on the one-year anniversary (08/17/2027); remaining 75% vests monthly in 1/36th installments thereafter, subject to continued service.
• Plan/Exemption: Granted under the Issuer's 2023 Equity Incentive Plan and exempt under Rule 16b-3.
• Additional note: Footnote states this filing does not include previously granted options to the reporting person. The filing does not state the total shares/options owned after this grant.

Context

• These are non-exercised option awards, meaning Poma has the right to buy shares in the future at $1.36 if and when vested and exercised. Because the strike equals the market price on the grant date, there was no immediate economic gain at grant. Grants are a common form of executive compensation and do not alone indicate buying or selling sentiment.